[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 24, 1999

Use of Antiretroviral Therapy by Intravenous Drug Users With HIV

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(8):699-701. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-8-jbk0224

To the Editor: Dr Celentano and colleagues1 describe some interesting data. We performed a cross-sectional study at the Catholic University in Rome, Italy, to assess predictive factors associated with adherence to ART in HIV-infected people receiving combination therapy with a PI. From April 1998 to July 1998, each consecutive HIV-infected patient attending the outpatient clinic and receiving triple combination ART with indinavir or ritonavir who provided informed consent was asked to fill out a questionnaire that included questions on the ART scheme they were currently taking (name, color, and timing), frequency and number of missed doses, reminder methods, frequency of running out of pills, reasons for treatment interruption, relationship with health care staff, presence of symptoms, and sociodemographic characteristics. Plasma level of PI as well as HIV viral load and CD4+ cell count were determined for each enrolled person. Clinic records were used to assess currently prescribed ART.

First Page Preview View Large
First page PDF preview
First page PDF preview
×